FDA Reverses Course on Sarepta, Approving DMD Gene Therapy for Patients Who Can Walk

FDA Reverses Course on Sarepta, Approving DMD Gene Therapy for Patients Who Can Walk

FDA Reverses Course on Sarepta, Approving DMD Gene Therapy for Patients Who Can Walk